KBY Biotech Indexv0.0.34
Search
← Pipeline|CAN-3547

CAN-3547

NDA/BLA
By Can-Fite BioPharma
Source: Trial-derived·Trials: 1
Modality
Multispecific
MOA
MALT1i
Target
FcRn
Pathway
PI3K/AKT
NBProstate Ca
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
~May 2019
→ ~Aug 2020
Phase 3
~Nov 2020
→ ~Feb 2022
NDA/BLA
May 2022
→ Jun 2031
NDA/BLACurrent
NCT03945869
2,045 pts·Prostate Ca
2022-05→2031-06·Terminated
2,045 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-235.2y awayPh3 Readout· Prostate Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2031-06-23 · 5.2y away
Prostate Ca
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03945869NDA/BLAProstate CaTerminated2045DAS28
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-2735Johnson & JohnsonPhase 2/3Cl18.2MALT1i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
RiboinavolisibJohnson & JohnsonPhase 2/3GLP-1RMALT1i
RHH-974RochePreclinicalJAK1MALT1i
NVS-3297NovartisPreclinicalCDK2MALT1i
GelinaritideAbbViePreclinicalFcRnCFTRmod
ABB-8985AbbViePhase 2CD20MALT1i
TalalemzoparlimabGilead SciencesPhase 1FcRnTNFi
SovafutibatinibModernaApprovedFcRnSHP2i
SovarelsinAlnylamPhase 2/3LAG-3MALT1i